COT drives resistance to RAF inhibition through MAP kinase pathway reactivation
Cory M. Johannessen, Jesse S. Boehm, So Young Kim et al. · Nature · 2010
Cited by 1,458 works. doi:10.1038/nature09627
Authors
- Cory M. Johannessen
- Jesse S. Boehm
- So Young Kim
- Sapana R. Thomas
- Leslie Wardwell
- Nicolas Stransky
- Alexandria P. Cogdill
- Jordi G Barretina
- Giordano Caponigro
- Haley Hieronymus
- Ryan R. Murray
- Kourosh Salehi‐Ashtiani
- DAVID EDWIN HILL
- Marc Vidal
- Jean J. Zhao
- Xiaoping Yang
- Ozan Alkan
References
- Mutations of the BRAF gene in human cancer
- Clinical Resistance to STI-571 Cancer Therapy Caused by BCR-ABL Gene Mutation or Amplification
- Inhibition of Mutated, Activated BRAF in Metastatic Melanoma
- MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling
- Mechanism of Activation of the RAF-ERK Signaling Pathway by Oncogenic Mutations of B-RAF
- The landscape of somatic copy-number alteration across human cancers
- BRAF mutation predicts sensitivity to MEK inhibition
- RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF
- Kinase-Dead BRAF and Oncogenic RAS Cooperate to Drive Tumor Progression through CRAF
- Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity